Elena Di Daniel

Summary

Affiliation: GlaxoSmithKline Research and Development
Country: USA

Publications

  1. ncbi Comparative analysis of the effects of four mood stabilizers in SH-SY5Y cells and in primary neurons
    Elena Di Daniel
    Schizophrenia and Bipolar Disorder Research Department, Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, Harlow, Essex, UK
    Bipolar Disord 7:33-41. 2005
  2. ncbi The common inositol-reversible effect of mood stabilizers on neurons does not involve GSK3 inhibition, myo-inositol-1-phosphate synthase or the sodium-dependent myo-inositol transporters
    Elena Di Daniel
    Schizophrenia and Bipolar Neurophysiology and Pharmacology Research Department, Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, Third Avenue, Harlow, Essex, CM19 5AW, UK
    Mol Cell Neurosci 32:27-36. 2006
  3. pmc Evaluation of expression and function of the H+/myo-inositol transporter HMIT
    Elena Di Daniel
    Psychiatry Discovery Technology Group, GlaxoSmithKline, New Frontiers Science Park, Harlow, UK
    BMC Cell Biol 10:54. 2009
  4. doi Investigation of the H(+)-myo-inositol transporter (HMIT) as a neuronal regulator of phosphoinositide signalling
    Elena Di Daniel
    Synaptic Plasticity and Neural Network Dynamics DPU, Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex, UK
    Biochem Soc Trans 37:1139-43. 2009
  5. doi Prolyl oligopeptidase binds to GAP-43 and functions without its peptidase activity
    Elena Di Daniel
    Psychiatry Discovery Technology Group, GlaxoSmithKline Pharmaceuticals, Harlow, Essex, UK
    Mol Cell Neurosci 41:373-82. 2009
  6. doi Neural network dysfunction in bipolar depression: clues from the efficacy of lamotrigine
    Charles H Large
    Neurosciences Centre of Excellence for Drug Discovery, Medicines Research Centre, GlaxoSmithKline S p A, Via Fleming 4, 37135, Verona, Italy
    Biochem Soc Trans 37:1080-4. 2009
  7. ncbi Expression and characterization of GSK-3 mutants and their effect on beta-catenin phosphorylation in intact cells
    Thilo Hagen
    Systems Research Kinase Biology Discovery Research, GlaxoSmithKline Pharmaceuticals, Harlow, Essex, CM19 5AD, United Kingdom
    J Biol Chem 277:23330-5. 2002

Detail Information

Publications7

  1. ncbi Comparative analysis of the effects of four mood stabilizers in SH-SY5Y cells and in primary neurons
    Elena Di Daniel
    Schizophrenia and Bipolar Disorder Research Department, Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, Harlow, Essex, UK
    Bipolar Disord 7:33-41. 2005
    ..We aimed to establish whether other mood-stabilizing drugs have a similar action and which signalling pathways mediate this process...
  2. ncbi The common inositol-reversible effect of mood stabilizers on neurons does not involve GSK3 inhibition, myo-inositol-1-phosphate synthase or the sodium-dependent myo-inositol transporters
    Elena Di Daniel
    Schizophrenia and Bipolar Neurophysiology and Pharmacology Research Department, Psychiatry Centre of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, Third Avenue, Harlow, Essex, CM19 5AW, UK
    Mol Cell Neurosci 32:27-36. 2006
    ..These results confirm that the common inositol-reversible effect of mood stabilizers on neurons does not involve GSK3 and further show that the effects are independent of MIP-synthase and SMIT transporters...
  3. pmc Evaluation of expression and function of the H+/myo-inositol transporter HMIT
    Elena Di Daniel
    Psychiatry Discovery Technology Group, GlaxoSmithKline, New Frontiers Science Park, Harlow, UK
    BMC Cell Biol 10:54. 2009
    ..Here, we describe analyses of expression and function of the recently identified H+/myo-inositol transporter (HMIT) investigated as a potential regulator of PIns signalling...
  4. doi Investigation of the H(+)-myo-inositol transporter (HMIT) as a neuronal regulator of phosphoinositide signalling
    Elena Di Daniel
    Synaptic Plasticity and Neural Network Dynamics DPU, Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex, UK
    Biochem Soc Trans 37:1139-43. 2009
    ..The neuronal-specific HMIT (H(+)-myo-inositol transporter) represents a potential regulator of inositol signalling in neurons that warrants further investigation...
  5. doi Prolyl oligopeptidase binds to GAP-43 and functions without its peptidase activity
    Elena Di Daniel
    Psychiatry Discovery Technology Group, GlaxoSmithKline Pharmaceuticals, Harlow, Essex, UK
    Mol Cell Neurosci 41:373-82. 2009
    ..Taken together, our results show that peptidase activity is not required for PO function in neurons and suggest that PO instead acts by binding to cytosolic proteins that control growth cone and synaptic function...
  6. doi Neural network dysfunction in bipolar depression: clues from the efficacy of lamotrigine
    Charles H Large
    Neurosciences Centre of Excellence for Drug Discovery, Medicines Research Centre, GlaxoSmithKline S p A, Via Fleming 4, 37135, Verona, Italy
    Biochem Soc Trans 37:1080-4. 2009
    ..The results are also consistent with the notion of corticolimbic network dysfunction in bipolar disorder...
  7. ncbi Expression and characterization of GSK-3 mutants and their effect on beta-catenin phosphorylation in intact cells
    Thilo Hagen
    Systems Research Kinase Biology Discovery Research, GlaxoSmithKline Pharmaceuticals, Harlow, Essex, CM19 5AD, United Kingdom
    J Biol Chem 277:23330-5. 2002
    ....